α粒子
阿尔法(金融)
癌症研究
细胞毒性
化学
白血病
放射化学
线性能量转移
癌症
药品
药理学
医学
免疫学
内科学
体外
生物化学
物理
外科
原子物理学
有机化学
离子
患者满意度
结构效度
作者
David A. Scheinberg,Michael R. McDevitt
出处
期刊:Current Radiopharmaceuticals
[Bentham Science]
日期:2011-10-01
卷期号:4 (4): 306-320
被引量:120
标识
DOI:10.2174/1874471011104040306
摘要
Alpha particle-emitting isotopes are being investigated in radioimmunotherapeutic applications because of their unparalleled cytotoxicity when targeted to cancer and their relative lack of toxicity towards untargeted normal tissue. Actinium- 225 has been developed into potent targeting drug constructs and is in clinical use against acute myelogenous leukemia. The key properties of the alpha particles generated by 225Ac are the following: i) limited range in tissue of a few cell diameters; ii) high linear energy transfer leading to dense radiation damage along each alpha track; iii) a 10 day halflife; and iv) four net alpha particles emitted per decay. Targeting 225Ac-drug constructs have potential in the treatment of cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI